Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy

MT Newswires Live

Nov 05

Zai Lab (HKG:9688) said bemarituzumab was found to be lacking in yet another clinical trial, according to a Hong Kong bourse filing Wednesday.

Shares of the biopharmaceutical company, which acquired the commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan from US-listed Amgen, fell over 3% in pre-market trade.

Zai Lab said the Fortitude-102 study evaluating bemarituzumab in combination with nivolumab and chemotherapy in treating gastric cancer was stopped for inadequate efficacy.

The drug was previously found to be lacking in the Fortitude-101 study, and the company had been awaiting results from Fortitude-102 for further clues of its usefulness in treating the patient population.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581522790"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581522790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581522790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581522790","market":"fut","top_or_hot":-1,"title":"Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (HKG:9688) said bemarituzumab was found to be lacking in yet another clinical trial, according to a Hong Kong bourse filing Wednesday.</p><p>Shares of the biopharmaceutical company, which acquired the commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan from US-listed Amgen, fell over 3% in pre-market trade.</p><p><a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> said the Fortitude-102 study evaluating bemarituzumab in combination with nivolumab and chemotherapy in treating gastric cancer was stopped for inadequate efficacy.</p><p>The drug was previously found to be lacking in the Fortitude-101 study, and the company had been awaiting results from Fortitude-102 for further clues of its usefulness in treating the patient population.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-05 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a> (HKG:9688) said bemarituzumab was found to be lacking in yet another clinical trial, according to a Hong Kong bourse filing Wednesday.</p><p>Shares of the biopharmaceutical company, which acquired the commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan from US-listed Amgen, fell over 3% in pre-market trade.</p><p><a href=\"https://laohu8.com/S/ZLAB\">Zai Lab</a> said the Fortitude-102 study evaluating bemarituzumab in combination with nivolumab and chemotherapy in treating gastric cancer was stopped for inadequate efficacy.</p><p>The drug was previously found to be lacking in the Fortitude-101 study, and the company had been awaiting results from Fortitude-102 for further clues of its usefulness in treating the patient population.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581522790","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581522790","pubTimestamp":1762307789,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zai Lab  said bemarituzumab was found to be lacking in yet another clinical trial, according to a Hong Kong bourse filing Wednesday.Shares of the biopharmaceutical company, which acquired the commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan from US-listed Amgen, fell over 3% in pre-market trade.Zai Lab said the Fortitude-102 study evaluating bemarituzumab in combination with nivolumab and chemotherapy in treating gastric cancer was stopped for inadequate efficacy.The drug was previously found to be lacking in the Fortitude-101 study, and the company had been awaiting results from Fortitude-102 for further clues of its usefulness in treating the patient population.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","09688":"再鼎医药","BK1588":"回港中概股","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"再鼎医药称Bemarituzumab研究因疗效不足而停止","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"Zai Lab (HKG:9688) said bemarituzumab was found to be lacking in yet another clinical trial, according to a Hong Kong bourse filing Wednesday.Shares of the biopharmaceutical company, which acquired the commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan from US-listed Amgen, fell over 3% in pre-market trade.Zai Lab said the Fortitude-102 study evaluating bemarituzumab in combination with nivolumab and chemotherapy in treating gastric cancer was stopped for inadequate efficacy.The drug was previously found to be lacking in the Fortitude-101 study, and the company had been awaiting results from Fortitude-102 for further clues of its usefulness in treating the patient population.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}